Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification
Journal of Hepatology · 2025-12 · 83 (6) · 1338-1352
DOI: 10.1016/j.jhep.2025.06.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatology, 2025-12. Verfasst von Yiling Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; State Key Laboratory of Liver Research, The …. Hauptthemen laut MEDLINE: Liver Neoplasms, Ubiquinone, Mevalonic Acid, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, The University of Hong Kong, Innovation and Technology Commission.
Abstract (Originalsprache)
BACKGROUND & AIMS: Ferroptosis has emerged as a promising therapeutic approach for hepatocellular carcinoma (HCC). To evade ferroptosis, HCC cells depend on the glutathione/GPX4 and CoQ10/FSP1 antioxidant systems. The mevalonate pathway enzyme mevalonate diphosphate decarboxylase (MVD) generates isopentenyl pyrophosphate (IPP), which supports both selenocysteine-tRNA modification and CoQ10 biosynthesis. Here, we investigated the role of the mevalonate pathway in HCC and explored novel vulnerabilities for therapeutic targeting. METHODS: The clinical relevance of MVD expression was assessed in human HCC samples. Regulation of MVD was examined using chromatin immunoprecipitation. Targeted metabolomics was performed to measure IPP and CoQ10 levels. Selenoprotein translation was evaluated via ribosome and polysome profiling. Multiple in vitro and in vivo HCC models were used to assess the efficacy of mevalonate pathway inhibitors. RESULTS: MVD was significantly overexpressed in human HCC tissues. Pharmacological inhibition of MVD using 6-FMEV reduced levels of IPP and CoQ10, suppressed selenoprotein translation, and triggered ferroptosis in HCC cells. Genetic ablation of TRSP (which encodes selenocysteine-tRNA) or TRIT1 (responsible for i6A tRNA modification) similarly blocked selenoprotein synthesis and induced ferroptosis. In mouse models, both 6-FMEV and atorvastatin (a clinically approved upstream mevalonate pathway inhibitor) effectively suppressed HCC tumor growth, including steatotic HCC. Moreover, mevalonate pathway inhibition showed synergistic anti-tumor effects when combined with either tyrosine kinase inhibitors or anti-PD-1 immunotherapy. CONCLUSIONS: Our findings reveal a critical link between the mevalonate pathway, CoQ10 production, and selenoprotein translation in protecting HCC cells from ferroptosis. The demonstrated anti-tumor role of 6-FMEV and atorvastatin supports the therapeutic potential of targeting the mevalonate pathway in HCC, either alone or in combination with existing treatments. IMPACT AND IMPLICATIONS: Current therapies show limited efficacy for advanced hepatocellular carcinoma (HCC). This study demonstrates that targeting the mevalonate pathway induces ferroptosis in HCC by disrupting CoQ10 biosynthesis and selenoprotein translation. Clinically relevant inhibitors, such as atorvastatin and the MVD inhibitor 6-FMEV, effectively suppressed tumor growth across multiple HCC subtypes in preclinical models. Furthermore, combining mevalonate pathway inhibitors with tyrosine kinase inhibitors or immune checkpoint inhibitors enhanced anti-tumor efficacy. These findings underscore the translational potential of mevalonate pathway inhibition as a novel therapeutic strategy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China; Centre for Oncology and Imm…
- Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Förderung
- National Natural Science Foundation of China
- The University of Hong Kong
- Innovation and Technology Commission
- Shenzhen Science and Technology Innovation Program
- Excellent Young Scientists Fund
- Li Ka Shing Faculty of Medicine, University of Hong Kong
- Shenzhen Science and Technology Innovation Commission
- Health and Medical Research Fund
Zitieren
APA
Chen, Y., Lee, D., Kwan, K. K., Wu, M., Wang, G., Zhang, M. S., Deng, H., Cheu, J. W., Lau, M. H., Chan, C. Y., Ooi, Z. Y., Wu, Y., Bao, M. H., Lo, R. C., Ng, I. O., Wong, C. M., & Wong, C. C. (2025). Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. Journal of Hepatology, 83(6), 1338-1352. https://doi.org/10.1016/j.jhep.2025.06.034
Vancouver
Chen Y, Lee D, Kwan KK, Wu M, Wang G, Zhang MS, et al. Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. Journal of Hepatology. 2025;83(6):1338-1352. doi:10.1016/j.jhep.2025.06.034
BibTeX
@article{Chen2025,
author = {Chen, Yiling and Lee, Derek and Kwan, Kenneth Kin-Leung and Wu, Mengjie and Wang, Gengchao and Zhang, Misty Shuo and Deng, Haijing and Cheu, Jacinth Wing-Sum and Lau, Mandy Ho-Ying and Chan, Cerise Yuen-Ki and Ooi, Zher Yee and Wu, Yibing and Bao, Macus Hao-Ran and Lo, Regina Cheuk-Lam and Ng, Irene Oi-Lin and Wong, Chun-Ming and Wong, Carmen Chak-Lui},
title = {Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification},
journal = {Journal of Hepatology},
year = {2025},
volume = {83},
number = {6},
pages = {1338--1352},
doi = {10.1016/j.jhep.2025.06.034}
}
EUVIMED